Trial Profile
A phase I, randomized, double-blind, placebo-controlled, inter-individual, ascending dose, multi-site study to assess the safety, tolerability, and pharmacokinetics of AMY109 after a single subcutaneous administration in healthy volunteers and after multiple subcutaneous administrations in patients with endometriosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs AMY 109 (Primary)
- Indications Endometriosis
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 16 Dec 2022 Status changed from recruiting to completed.
- 01 Jun 2018 Planned number of patients changed from 80 to 112.
- 01 Jun 2018 Planned End Date changed from 1 Dec 2018 to 1 Oct 2020.